For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Scope of the Report:
This report focuses on the Urokinase in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The global Urokinase industry has a rather high concentration. The major manufacturers are concentrated in China, such as NDPharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma and Jiangsu Aidea Pharmaceutica. At present, NDPharm is the world leader, holding 61.93% production market share in 2016.
In 2016, the global Urokinase consumption market is led by China and China is the largest region consumption market, accounting for about 18.58% of global consumption of Urokinase.
Urokinase downstream is wide and recently Urokinase has acquired increasing significance in various fields of Hospital, Clinic and others. Globally, the Urokinase market is mainly driven by growing demand for Hospital. Hospital accounts for nearly 78.59% of total downstream consumption of Urokinase in global.
The worldwide market for Urokinase is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Wanhua Biochem
- Jiangxi Haoran Bio-Pharma
- Jiangsu Aidea Pharmaceutical
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Urokinase Powder
- Urokinase Solution
Market Segment by Applications, can be divided into
There are 15 Chapters to deeply display the global Urokinase market.
Chapter 1, to describe Urokinase Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Urokinase, with sales, revenue, and price of Urokinase, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Urokinase, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Urokinase market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Urokinase sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source